Press releases

11
Oct 2022
20:30 E.S.T.

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Read more
5
Oct 2022
20:30 E.S.T.

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Read more
28
Sep 2022
20:25 E.S.T.

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

Read more
1
Sep 2022
20:30 E.S.T.

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

Read more
4
Aug 2022
20:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

Read more
1
Aug 2022
20:30 E.S.T.

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

Read more
28
Jul 2022
20:30 E.S.T.

Cellectis to Report Second Quarter 2022 Financial Results

Read more
30
Jun 2022
09:00 E.S.T.

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

Read more
28
Jun 2022
20:30 E.S.T.

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Read more
28
Jun 2022
20:05 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US